Market leadership Covance Drug Development is a leading global CRO with a track record of supporting top pharmaceutical and biotech companies across the full drug development lifecycle, presenting opportunities to position Labcorp’s broader capabilities and premium services to potential clients seeking Comprehensive CRO partnerships.

Integrated capabilities As the drug development arm of Labcorp, Covance offers end-to-end services beyond testing, enabling cross-sell opportunities for clients needing integrated solutions across preclinical to late-stage development and potential collaboration with Labcorp’s broader diagnostics and research platforms.

Recent investments Facilities investments in preclinical oncology and selective unit leadership changes signal growth and expanded capabilities, suggesting timely outreach to oncology-focused sponsors and teams building capabilities in cell and gene therapy and specialized preclinical services.

Awards and recognition Multiple industry accolades (CRO of the Year, Markie recognition, quality awards) reinforce credibility and can be used to support outreach to risk-averse sponsors seeking proven quality, reliability, and award-winning performance in CRO partnerships.

Strategic partnerships Past collaborations, including Tempus partnerships and a strong focus on nonclinical safety and advanced analytics, highlight opportunities to propose joint programs or data-driven study designs, appealing to sponsors looking to accelerate timelines with innovative tech-enabled solutions.